YY1 and neoplasm: In addition, while existing checkpoint inhibitors focus on immune cells, YY1′s role in tumor cells—regulating PD-L1 expression, proliferation, metastasis, and resistance—provides an opportunity for dual-action therapies that target both tumor progression and immune escape mechanisms.